Pomelo Care announced it raised $92 million in Series C funding at a $1.7 billion valuation as it moves to broaden its virtual, evidence-based care model beyond maternity into a wider set of women’s and children’s health needs across the lifespan.
The round was led by Stripes, with participation from Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel, according to the company. Founded in 2021, Pomelo partners with health plans and employers and said it now covers more than 25 million lives and supports nearly 7% of U.S. births through a 24/7 virtual care model delivered by a multispecialty clinical team.
Pomelo said its approach combines continuous monitoring with data science to identify risks early and coordinate care alongside in-person providers. The company positioned its offering as a way to help address access gaps and clinician capacity constraints while improving outcomes and lowering costs.
As part of its pitch to payers and employers, Pomelo cited claims-based results it said it has published and presented at national scientific and medical conferences, including a 37% reduction in preterm births, a 46% reduction in emergency room utilization, and a 6.8-day reduction in NICU length of stay, including 16.3 days for complex cases. The company also reported a 718% increase in prenatal depression screening and follow-up rates, and said customer engagement has been associated with a 3x to 5x return on investment driven by lower rates of preterm births, emergency visits, and NICU stays.
The company said its “intelligent care platform” embeds evidence-based pathways and predictive analytics into clinician workflows to surface and update risks as a patient’s care journey evolves. For patients, Pomelo said the platform supports multimodal access—phone, text, call, video, and app—to a care team that can include nurses, dietitians, therapists, doulas, and providers able to diagnose, treat, and manage care.
With the new funding, Pomelo said it will continue scaling its maternity offering while applying the same clinical and accountability framework to additional programs spanning reproductive health, pediatrics, hormonal health, perimenopause and menopause, and longer-term preventive and chronic condition management. The company also highlighted a newer midlife care program focused on perimenopause and menopause, reporting an 88% reduction in symptoms on the Menopause Rating Scale over 60 days and 73% of patients saying they experienced improved productivity after joining.
KEY QUOTES:
“Pomelo Care was founded to measurably improve maternal health in the United States. We’ve demonstrated that when care is proactive, evidence-based, and accountable, we improve outcomes and costs come down. Now, with this funding, we’re taking that proven model beyond maternity to build a system of care that supports women and children throughout their lives, delivering better results across the entire healthcare ecosystem—for patients, payers, providers, and employers alike.”
Marta Bralic Kerns, Founder & CEO, Pomelo Care
“Pomelo has reached national scale at an unprecedented rate — now serving 25 million covered lives through Commercial and Medicaid health plan partnerships across the United States. The power of Pomelo’s amazing product is clear: exceptional patient satisfaction and strong clinical results showing meaningful reductions in pregnancy-related complications. We believe Pomelo’s intelligent care platform will power continued rapid growth and product expansion, meeting rising demand from patients and payers with a modern clinical experience and best-in-class operating metrics.”
Ron Shah, Partner, Stripes
